Guilherme Silva
University of Texas at Austin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Guilherme Silva.
American Heart Journal | 2010
James T. Willerson; Emerson C. Perin; Stephen G. Ellis; Carl J. Pepine; Timothy D. Henry; David Zhao; Dejian Lai; Marc S. Penn; Barry J. Byrne; Guilherme Silva; Adrian P. Gee; Jay H. Traverse; Antonis K. Hatzopoulos; John R. Forder; Daniel Martin; Marvin Kronenberg; Doris A. Taylor; Christopher R. Cogle; Sarah Baraniuk; Lynette Westbrook; Shelly L. Sayre; Rachel W. Vojvodic; David J. Gordon; Sonia I. Skarlatos; Lemuel A. Moyé; Robert D. Simari
BACKGROUNDnThe increasing worldwide prevalence of coronary artery disease (CAD) continues to challenge the medical community. Management options include medical and revascularization therapy. Despite advances in these methods, CAD is a leading cause of recurrent ischemia and heart failure, posing significant morbidity and mortality risks along with increasing health costs in a large patient population worldwide.nnnTRIAL DESIGNnThe Cardiovascular Cell Therapy Research Network (CCTRN) was established by the National Institutes of Health to investigate the role of cell therapy in the treatment of chronic cardiovascular disease. FOCUS is a CCTRN-designed randomized, phase II, placebo-controlled clinical trial that will assess the effect of autologous bone marrow mononuclear cells delivered transendocardially to patients with left ventricular (LV) dysfunction and symptomatic heart failure or angina. All patients need to have limiting ischemia by reversible ischemia on single-photon emission computed tomography assessment.nnnRESULTSnAfter thoughtful consideration of both statistical and clinical principles, we will recruit 87 patients (58 cell treated and 29 placebo) to receive either bone marrow-derived stem cells or placebo. Myocardial perfusion, LV contractile performance, and maximal oxygen consumption are the primary outcome measures.nnnCONCLUSIONSnThe designed clinical trial will provide a sound assessment of the effect of autologous bone marrow mononuclear cells in improving blood flow and contractile function of the heart. The target population is patients with CAD and LV dysfunction with limiting angina or symptomatic heat failure. Patient safety is a central concern of the CCTRN, and patients will be followed for at least 5 years.
Archive | 2006
Emerson C. Perin; Guilherme Silva; T James Willerson.
An essential guide to cardiac cell therapy / , An essential guide to cardiac cell therapy / , کتابخانه دیجیتال جندی شاپور اهواز
Archive | 2006
Emerson C. Perin; Guilherme Silva; James T. Willerson
Archive | 2009
Emerson C. Perin; Guilherme Silva; James T. Willerson
Archive | 2007
Emerson C. Perin; Guilherme Silva; James T. Willerson
Archive | 2007
Emerson C. Perin; Guilherme Silva
Archive | 2007
Emerson C. Perin; Guilherme Silva; Pilar Jiménez-Quevedo
Rev. bras. cardiol. invasiva | 2006
Marlos R. Fernandes; Guilherme Silva; Rosella Madona; Edie M. Oliveira; Willian Vaughn; Rodrigo Branco; Pilar Jiménez-Quevedo; Ricardo Sanz-Ruiz; Franca Stedile Angeli; Fredt Baimbridge; Robert Falotico; Fredt Clubb; Emerson C. Perin
Archive | 2006
Emerson C. Perin; Guilherme Silva; James T. Willerson
Archive | 2006
Emerson C. Perin; Guilherme Silva; James T. Willerson